Press release - 18/05/2021 BBI JU to invest €104.5 million into circular bio-based projects The Bio-based Industries Joint Undertaking (BBI JU) has signed the grant agreements with 18 new projects, selected for funding under the 2020 Call for proposals. 199 beneficiaries from 26 countries across the EU and beyond will receive BBI JU’s financial support worth €104.5 million. This is the seventh and last BBI JU call which will bring the total investment of the initiative to €821.6 million and the BBI JU’s portfolio to 142 projects. https://www.biooekonomie-bw.de/en/articles/pm/bbi-ju-invest-eur1045-million-circular-bio-based-projects
Press release - 23/04/2021 For which plastic products is biodegradation a viable endof- life option? The BioSinn project found products and applications for which biodegradation at the end-of-life is a real option. 25 fact sheets answer technical and regulatory questions for each application. The market volume of these applications was also estimated: in Germany it is about 170,000 tonnes, in the European Union about 1 million tonnes per year!https://www.biooekonomie-bw.de/en/articles/pm/bei-welchen-kunststoffprodukten-ist-der-biologische-abbau-eine-sinnvolle-end-life-option
Press release - 21/04/2021 A study identifies the top 50 life and biological sciences and technologies driving innovation in the bio-based sectors in Europe. The study “Life and Biological Sciences and Technologies as Engines for Bio-based Innovation”, funded by the European Commission, DG Research and Innovation has been published and is now available for download from the website of the Publications Office of the European Union.https://www.biooekonomie-bw.de/en/articles/pm/study-identifies-top-50-life-and-biological-sciences-and-technologies-driving-innovation-bio-based-sectors-europe
Press release - 23/02/2021 Commission gives the green light to the successor of BBI JU The European Commission agreed on the successor of BBI JU – the Circular Bio-based Europe Joint Undertaking (CBE JU) in a legislative proposal adopted today. The new partnership between the EU and the Bio-based Industries Consortium (BIC) is expected to build on the success of BBI JU while stepping up its contribution to the EU’s climate targets, in line with the European Green Deal. The European Parliament and Council will now study the…https://www.biooekonomie-bw.de/en/articles/pm/commission-gives-green-light-successor-bbi-ju
Press release - 29/01/2021 The added value of compostable plastics for the circular economy For quite some time now, the European Commission (EC) is putting a special focus on biodegradable and compostable polymers when assessing the general role of bioplastics. https://www.biooekonomie-bw.de/en/articles/pm/added-value-compostable-plastics-circular-economy
Press release - 26/01/2021 Report on the Mapping of Biomass Value Chains for Improved Sustainable Energy use in the Baltic Sea Region Countries Published The University of Warmia and Mazury in Olsztyn, Polish partner of the BalticBiomass4Value project, published a report which maps biomass value chains for improved sustainable energy use in the Baltic Sea Region countries. The research focuses on the 9 Baltic Sea Region (BSR) countries: Denmark, Germany, Estonia, Finland, Latvia, Lithuania, Poland, Sweden, and Norway.https://www.biooekonomie-bw.de/en/articles/pm/report-mapping-biomass-value-chains-improved-sustainable-energy-use-baltic-sea-region-countries-published
Press release - 07/01/2021 CureVac and Bayer join forces on COVID-19 vaccine candidate CVnCoV Bayer has signed a collaboration and services agreement with CureVac, a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid. Under the terms of the agreement, Bayer will support the further development, supply and key territory operations of CureVac´s COVID-19 vaccine candidate CVnCoV. https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-and-bayer-join-forces-covid-19-vaccine-candidate-cvncov
Development of the genomDE genome database - 04/12/2020 Whole genome sequencing for diagnosing rare diseases Grouped together, rare diseases are by no means a rare phenomenon; however, they are rarely correctly diagnosed and rarely properly treated. In most cases, there is no effective medication available. Rare disease centres staffed by experts have been set up in many German cities to speed up the often long and painful search for the right diagnosis and treatment. Whole genome sequencing is a component of general healthcare, used to identify…https://www.gesundheitsindustrie-bw.de/en/article/news/whole-genome-sequencing-diagnosing-rare-diseases
Funding European Circular Bioeconomy Fund Funding programme, Funded by: European Investment Bank (EIB), European countries/National Promotional Banks, Industry investors, Financial investorshttps://www.bio-pro.de/en/database/funding/european-circular-bioeconomy-fund
Funding European Circular Bioeconomy Fund Funding programme, Funded by: European Investment Bank (EIB), European countries/National Promotional Banks, Industry investors, Financial investorshttps://www.biooekonomie-bw.de/en/databases/funding/european-circular-bioeconomy-fund
Stem cell therapy for regenerating intervertebral discs - 16/07/2020 Ulm’s simulator has Europe’s back Back pain is often caused by intervertebral disc disorders. Much has already been tried and is available to help patients. Despite extensive progress, there is still no surefire recipe for success. iPSpine, an EU-funded project to which researchers from Ulm are contributing interdisciplinary engineering and biomedical expertise, aims to design a novel therapy for back pain based on intervertebral disc regeneration.https://www.gesundheitsindustrie-bw.de/en/article/news/Ulms-simulator-has-europes-back
Dossier - 28/04/2020 Sustainable bioenergy Biomass from forestry and agriculture along with residues from industry and households can contribute to our energy and raw material shift. Sustainable, regenerative biomass-based energy can become part of the energy mix of the future within the framework of a bioeconomy.https://www.biooekonomie-bw.de/en/articles/news/Sustainable-bioenergy
Article - 21/03/2019 Education as the key to a successful transition into a bioeconomy National and international policy papers emphasize the role of the education sector in the transition into a bioeconomy. On the practical level, various actors are working on programmes to prepare professionals for future challenges. The University of Hohenheim, for example, offers a bioeconomy master's programme and is one of the universities that have laid the cornerstone for the “European Bioeconomy University” consortium. https://www.biooekonomie-bw.de/en/articles/news/bildung-als-schluessel-fuer-eine-erfolgreiche-biooekonomie-transformation
Event - 24/04/2019 Challenges and Opportunities of Eco-construction in Southeast Europe Zagreb (Croatia), Workshop https://www.bio-pro.de/en/events/past-events/challenges-and-opportunities-of-eco-construction-in-southeast-europe
High-tech - 20/10/2016 Industry 4.0 in the medical technology and pharmaceutical industry sectors https://www.gesundheitsindustrie-bw.de/en/article/dossier/industry-40-in-the-medical-technology-and-pharmaceutical-industry-sectors
Dossier - 03/06/2013 Food analytics applied consumer protection https://www.gesundheitsindustrie-bw.de/en/article/dossier/food-analytics-applied-consumer-protection
Dossier - 21/05/2013 No new drugs to be placed on the market without clinical trials New pharmaceuticals are subject to approval by drug authorities. Prior to approval of a new pharmaceutical several hurdles such as preclinical and clinical studies need to be cleared. Clinical trials are performed to ensure the quality efficacy and safety of a medicinal product. Clinical development is a time-consuming and costly process and takes on average ten to fifteen years before a pharmaceutical company can apply for the approval of the…https://www.gesundheitsindustrie-bw.de/en/article/dossier/no-new-drugs-to-be-placed-on-the-market-without-clinical-trials
Dossier - 10/09/2012 Horizon 2020 the EU framework programme for research and innovation a boost for top-level research in Europe In the face of the ongoing financial crisis Europe is working on a new research strategy that is aimed at creating new economic growth and jobs. The new EU framework programme for research and innovation Horizon 2020 replaces the 7th Framework Programme FP7 and will run from 2014 with a budget of 80 billion. In July 2012 Brussels launched the final FP7 calls for proposals for 2013 that offer numerous market-based instruments designed to bridge…https://www.gesundheitsindustrie-bw.de/en/article/dossier/horizon-2020-the-eu-framework-programme-for-research-and-innovation-a-boost-for-top-level-research-i
Dossier - 10/09/2012 Horizon 2020 the EU framework programme for research and innovation a boost for top-level research in Europe In the face of the ongoing financial crisis Europe is working on a new research strategy that is aimed at creating new economic growth and jobs. The new EU framework programme for research and innovation Horizon 2020 replaces the 7th Framework Programme FP7 and will run from 2014 with a budget of 80 billion. In July 2012 Brussels launched the final FP7 calls for proposals for 2013 that offer numerous market-based instruments designed to bridge…https://www.biooekonomie-bw.de/en/articles/dossiers/horizon-2020-the-eu-framework-programme-for-research-and-innovation-a-boost-for-top-level-research-i